OPA1 and lung adenocarcinoma: These findings suggest that modulating mitochondrial dynamics may be a potential strategy to prevent metastatic chemotherapy resistance.250 Additionally, Opa1 contributes to resistance to gefitinib, an inhibitor of tyrosine kinases, in a lung adenocarcinoma (LUAD) cell line.251 Tht gefitinib-resistant LUAD cells exhibit elongated mitochondria with narrower cristae and elevated Opa1 expression levels.